|
1
|
Ishii KA and Takamura T: Non-alcoholic
fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)
and nutrition. Clin Calcium. 26:363–367. 2016.(In Japanese).
PubMed/NCBI
|
|
2
|
Moghaddasifar I, Lankarani KB, Moosazadeh
M, Afshari M, Ghaemi A, Aliramezany M, Gharebagh Afsar R and Malary
M: Prevalence of non-alcoholic fatty liver disease and its related
factors in Iran. Int J Organ Transplant Med. 7:149–160.
2016.PubMed/NCBI
|
|
3
|
Ruhl CE and Everhart JE: Fatty liver
indices in the multiethnic united states national health and
nutrition examination survey. Aliment Pharm Therap. 41:65–76. 2015.
View Article : Google Scholar
|
|
4
|
Fung J, Lee CK, Chan M, Seto WK, Lai CL
and Yuen MF: Hong Kong Liver Health Census Study Group: High
prevalence of non-alcoholic fatty liver disease in the
Chinese-results from the Hong Kong liver health census. Liver Int.
58:542–549. 2015. View Article : Google Scholar
|
|
5
|
Iftikhar R, Kamran SM, Sher F and Wahla
MS: Prevalence of non alcoholic fatty liver disease in patients
with metabolic syndrome. PAFMJ. 65:616–619. 2015.
|
|
6
|
Mehal WZ: The Gordian Knot of dysbiosis,
obesity and NAFLD. Nat Rev GastroHepat. 10:637–644. 2013.
|
|
7
|
Manan B and Saraswat VA: Gut-liver axis:
Role of inflammasomes. J Clin Exp Hepatol. 3:141–149. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strowig T, Henao-Mejia J, Elinav E and
Flavell R: Inflammasomes in health and disease. Nature.
481:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Henao-Mejia J, Elinav E, Jin C, Hao L,
Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ,
et al: Inflammasome-mediated dysbiosis regulates progression of
NAFLD and obesity. Nature. 482:179–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dixon LJ, Berk M, Thapaliya S, Papouchado
BG and Feldstein AE: Caspase-1-mediated regulation of fibrogenesis
in diet-induced steatohepatitis. Lab Invest. 92:713–723. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petrasek J, Bala S, Csak T, Lippai D,
Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA and Szabo G:
IL-1 receptor antagonist ameliorates inflammasome-dependent
alcoholic steatohepatitis in mice. J Clin Invest. 122:3476–3489.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Csak T, Ganz M, Pespisa J, Kodys K,
Dolganiuc A and Szabo G: Fatty acid and endotoxin activate
inflammasomes in mouse hepatocytes that release danger signals to
stimulate immune cells. Hepatology. 54:133–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wree A, Mcgeough MD, Peña CA, Schlattjan
M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM and
Feldstein AE: NLRP3 inflammasome activation is required for
fibrosis development in NAFLD. J Mol Med (Berl). 92:1069–1082.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin P, Lu J, Wang Y, Gu W, Yu J and Zhao
RH: Naturally occurring stilbenoid TSG reverses non-alcoholic fatty
liver diseases via gut-liver axis. PLoS One. 10:01403462015.
View Article : Google Scholar
|
|
15
|
Wang W, He Y, Lin P, Li Y, Sun R, Gu W, Yu
J and Zhao R: In vitro effects of active components of Polygoni
Multiflori Radix on enzymes involved in the lipid metabolism. J
Ethnopharmacol. 153:763–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin P, He YR, Lu JM, Li N, Wang WG, Gu W,
Yu J and Zhao RH: In vivo lipid regulation mechanism of polygoni
multiflori radix in high-fat diet fed rats. Evid Based Complement
Alternat Med. 2014:6420582014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li N, Chen Z, Mao XJ, Yu J and Zhao RH:
Effects of lipid regulation using raw and processed radix polygoni
multiflori in rats fed a high-fat diet. Evid Based Complement
Alternat Med. 2012:3291712012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang M, Zhao R, Wang W, Mao X and Yu J:
Lipid regulation effects of polygoni multiflori radix, its
processed products and its major substances on steatosis human
liver cell line L02. J Ethnopharmacol. 139:287–293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang SJ and Lim Y: Resveratrol ameliorates
hepatic metaflammation and inhibits NLRP3 inflammasome activation.
Metabolism. 63:693–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
CaporasoJ G, Kuczynski J, Stombaugh J,
Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich
JK, Gordon JI, et al: QIIME allows analysis of high-throughput
community sequencing data. Nat Methods. 7:335–336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Magoč T and Salzberg SL: FLASH: Fast
length adjustment of short reads to improve genome assemblies.
Bioinformatics. 27:2957–2963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao ZM and Vance DE: Reduction in VLDL,
but not HDL, in plasma of rats deficient in choline. Biochem Cell
Biol. 68:552–558. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bieghs V and Trautwein C: The innate
immune response during liver inflammation and metabolic disease.
Trends Immunol. 34:446–452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okubo H, Sakoda H, Kushiyama A, Fujishiro
M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T,
Yoshida Y, et al: Lactobacillus casei strain Shirota protects
against nonalcoholic steatohepatitis development in a rodent model.
Am J Physiol Gastrointest Liver Physiol. 305:G911–G918. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Endo H, Niioka M, Kobayashi N, Tanaka M
and Watanabe T: Butyrate-producing probiotics reduce nonalcoholic
fatty liver disease progression in rats: New insight into the
probiotics for the gut-liver axis. PLoS One. 8:00633882013.
View Article : Google Scholar
|
|
26
|
Miura K and Ohnishi H: Role of gut
microbiota and Toll-like receptors in nonalcoholic fatty liver
disease. World J Gastroentero. 20:7381–7391. 2014. View Article : Google Scholar
|
|
27
|
Lee SM, Han HW and Yim SY: Beneficial
effects of soy milk and fiber on high cholesterol diet-induced
alteration of gut microbiota and inflammatory gene expression in
rats. Food Funct. 6:492–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harris JK, El Kasmi KC, Anderson AL,
Devereaux MW, Fillon SA, Robertson CE, Wagner BD, Stevens MJ, Pace
NR and Sokol RJ: Specific microbiome changes in a mouse model of
parenteral nutrition associated liver injury and intestinal
inflammation. PLoS One. 9:01103962014. View Article : Google Scholar
|
|
29
|
Del Chierico F, Gnani D, Vernocchi P,
Petrucca A, Alisi A, Dallapiccola B, Nobili V and Lorenza P:
Meta-omic platforms to assist in the understanding of NAFLD gut
microbiota alterations: tools and applications. Int J Mol Sci.
15:684–711. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koch KN and Müller A: Helicobacter pylori
activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory
T-cells, establish persistent infection and promote tolerance to
allergens. Gut Microbes. 6:382–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barlow GM, Yu A and Mathur R: Role of the
gut microbiome in obesity and diabetes mellitus. Nutr Clin Pract.
30:787–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Everarda A, Belzerb C, Geurtsa L,
Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli
GG, Delzenne NM, et al: Cross-talk between Akkermansia muciniphila
and intestinal epithelium controls diet-induced obesity. Proc Natl
Acad Sci USA. 110:9066–9071. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Itagaki H, Shimizu K, Morikawa S, Ogawa K
and Ezaki T: Morphological and functional characterization of
non-alcoholic fatty liver disease induced by a
methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp
Patho. 6:2683–2696. 2013.
|
|
34
|
Leclercq IA, Farrell GC, Field J, Bell DR,
Gonzalez FJ and Robertson GR: CYP2E1 and CYP4A as microsomal
catalysts of lipid peroxides in murine nonalcoholic
steatohepatitis. J Clin Invest. 105:1067–1075. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oliveira CP, da Costa Gayotto LC, Tatai C,
Della Bina BI, Janiszewski M, Lima ES, Abdalla DS, Lopasso FP,
Laurindo FR and Laudanna AA: Oxidative stress in the pathogenesis
of nonalcoholic fatty liver disease, in rats fed with a
choline-deficient diet. J Cell Mol Med. 6:399–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wree A, Eguchi A, McGeough MD, Pena CA,
Johnson CD, Canbay A, Hoffman HM and Feldstein AE: NLRP3
inflammasome activation results in hepatocyte pyroptosis, liver
inflammation, and fibrosis in mice. Hepatology. 59:898–910. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fukui H: Gut microbiota and host reaction
in liver diseases. Microorganisms. 3:759–791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bawa M and Saraswat V: Gut-liver axis:
Role of inflammasomes. J Clin Exp Hepatol. 3:141–149. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Capiralla H, Vingtdeux V, Zhao H,
Sankowski R, Al-Abed Y, Davies P and Marambaud P: Resveratrol
mitigates lipopolysaccharide- and Aβ-mediated microglial
inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J
Neurochem. 120:461–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yi CO, Jeon BT, Shin HJ, Jeong EA, Chang
KC, Lee JE, Lee DH, Kim HJ, Kang SS, Cho GJ, et al: Resveratrol
activates AMPK and suppresses LPS-induced NF-κB-dependent COX-2
activation in RAW 264.7 macrophage cells. Anat Cell Biol.
44:194–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang C, Wang Y, Wang J, Yao W, Chen X and
Zhang W: TSG (2,3,4′,5-tetrahydroxystilbene 2-O-β-D-glucoside)
suppresses induction of pro-inflammatory factors by attenuating the
binding activity of nuclear factor-κB in microglia. J
Neuroinflammation. 10:1292013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saiko P, Szakmary A, Jaeger W and Szekeres
T: Resveratrol and its analogs: Defense against cancer, coronary
disease and neurodegenerative maladies or just a fad? Mutat Res.
658:68–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chao JF, Li HT, Cheng KW, Yu MS, Chang RC
and Wang M: Protective effects of pinostilbene, a resveratrol
methylated derivative, against 6-hydroxydopamine-induced
neurotoxicity in SH-SY5Y cells. J Nutr Biochem. 21:482–489. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Larrosa M, Tomé-Carneiro J, Yáñez-Gascón
MJ, Alcántara D, Selma MV, Beltrán D, García-Conesa MT, Urbán C,
Lucas R, Tomás-Barberán F, et al: Preventive oral treatment with
resveratrol pro-prodrugs drastically reduce colon inflammation in
rodents. J Med Chem. 53:7365–7376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou XX, Yang Q, Xie YH, Sun JY, Qiu PC,
Cao W and Wang SW: Protective effect of tetrahydroxystilbene
glucoside against D-galactose inducedaging process in mice.
Phytochem Lett. 6:372–378. 2013. View Article : Google Scholar
|
